OSE Immunotherapeutics Expands Lusvertikimab Program with New Autoimmune Indications in 2026-2028 Strategic Plan
Key Insights
OSE Immunotherapeutics announced expansion of lusvertikimab into chronic pouchitis (search) and hidradenitis suppurativa (search) as part of its 2026-2028 strategic plan targeting autoimmune diseases.
The company plans to initiate a Phase 2 clinical trial in the second half of 2026, subject to funding, while transitioning ulcerative colitis (search) indication to subcutaneous formulation.
Strategic approach includes developing lusvertikimab IV in rare/specialty indications requiring modest financial investment compared to further UC development.
OSE Immunotherapeutics has unveiled an ambitious expansion of its lusvertikimab program, targeting chronic pouchitis (search) and hidradenitis suppurativa (search) as new autoimmune indications within its comprehensive 2026-2028 strategic plan. The French biotech company selected these conditions based on their biological rationale with IL-7R (search), the target of lusvertikimab, marking a strategic diversification beyond its existing ulcerative colitis (search) program.
Strategic Expansion into Targeted Autoimmune Diseases
The company's balanced diversification strategy positions chronic pouchitis (search) as a short-term rare disease opportunity, while hidradenitis suppurativa (search) represents a medium-term dermatology indication. This approach complements the existing ulcerative colitis (search) program and reflects OSE's commitment to expanding lusvertikimab's therapeutic potential across multiple immune-mediated conditions.
Marc Le Bozec, Chief Executive Officer at OSE Immunotherapeutics, emphasized the strategic focus: "This strategy positions OSE for success by concentrating resources where they can create the most value for all our stakeholders over the next three years. It's ambitious yet realistic for a company our size."
Clinical Development Timeline and Formulation Strategy
OSE plans to initiate its first Phase 2 clinical trial in the second half of 2026, contingent on securing adequate funding. The company will leverage its existing intravenous formulation to target one or two new rare or specialty diseases with high unmet medical needs, utilizing a precision medicine approach that requires more modest financial investment than further development in ulcerative colitis (search).
Simultaneously, OSE is transitioning its ulcerative colitis (search) indication to a subcutaneous formulation of lusvertikimab. The company aims to establish a partnership once bioequivalence data are obtained, recognizing that the overall UC market focuses almost entirely on more convenient oral and subcutaneous formulations rather than intravenous delivery.
Biomarker Validation and Precision Medicine Approach
A key component of the strategic plan involves generating additional scientific data to validate a potentially predictive biomarker identified in the Phase 2 CoTikiS study. This biomarker appears predictive of strong clinical response in approximately 25% of patients tested in the lusvertikimab IV Phase 2 trial.
Confirming these early findings could position lusvertikimab subcutaneous formulation in ulcerative colitis (search) as a game changer, potentially allowing well over 30% of treated patients to achieve clinical remission. This development would significantly enhance the asset's attractiveness for potential partners and strengthen its competitive position in the UC market.
Comprehensive Strategic Framework
The expansion represents one of four value-creating opportunities in OSE's strategic plan, alongside completing Tedopi's Artemia Phase 3 trial in non-small cell lung cancer (search), developing subcutaneous formulation and combination strategies for lusvertikimab in UC, and maintaining scientific leadership through the company's differentiated research engine.
Financial Positioning and Partnership Strategy
OSE Immunotherapeutics currently maintains financial visibility until early Q4 2026, excluding additional financing or milestone payments from existing partnerships. The company aims to limit shareholder dilution while securing reasonable cash runway through complementary financing options, including equity, new debt, and restructuring of existing debt.
The strategic plan requires significantly less investment than the previously planned Phase 2b for lusvertikimab IV in ulcerative colitis (search), though additional financial resources will be necessary for completion. OSE may also receive milestone payments under current agreements, notably a EUR 17.5 million payment from Boehringer Ingelheim related to the 2024 acquisition of a cis-targeting anti-PD-1/cytokine asset, which would substantially reduce financing needs.